Proficio Capital Partners LLC Makes New $358,000 Investment in Envista Holdings Co. (NYSE:NVST)

Proficio Capital Partners LLC bought a new position in Envista Holdings Co. (NYSE:NVST) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 18,576 shares of the company’s stock, valued at approximately $358,000.

Other institutional investors have also added to or reduced their stakes in the company. Huntington National Bank increased its stake in Envista by 97.8% in the 3rd quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after acquiring an additional 949 shares during the last quarter. Venturi Wealth Management LLC boosted its holdings in shares of Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock worth $38,000 after purchasing an additional 1,638 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after purchasing an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Envista in the 4th quarter worth about $53,000. Finally, US Bancorp DE boosted its holdings in shares of Envista by 150.6% in the 3rd quarter. US Bancorp DE now owns 4,971 shares of the company’s stock worth $98,000 after purchasing an additional 2,987 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NVST. JPMorgan Chase & Co. cut their price objective on Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. UBS Group cut their price objective on Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Monday. Wells Fargo & Company set a $19.00 target price on Envista in a report on Saturday. Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday, March 6th. Finally, Mizuho began coverage on Envista in a report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price for the company. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, Envista presently has an average rating of “Hold” and an average price target of $20.18.

Envista Trading Down 4.8 %

NYSE NVST opened at $17.55 on Tuesday. Envista Holdings Co. has a fifty-two week low of $15.15 and a fifty-two week high of $23.00. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04. The stock has a 50 day simple moving average of $20.19 and a two-hundred day simple moving average of $19.70. The stock has a market cap of $3.02 billion, a P/E ratio of -2.70, a price-to-earnings-growth ratio of 1.27 and a beta of 1.33.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current year.

Envista Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.